In the News

400 News Items found
Dr. Rona Yaeger
The targeted therapy adagrasib received accelerated approved for colorectal cancer caused by a mutation called KRAS-G12C, when used in combination with the drug cetuximab. MSK investigators have led much of the research that resulted in this combined drug approval.
Adrienne Boire at the lab bench
In the Lab
Research is providing new clues about how cancer spreads to spinal fluid, a condition called leptomeningeal metastasis.
Colored x-ray of lung cancer
In the Lab
Researchers are developing uses for a drug that could benefit many people with lung cancer.
Bob Li, MD, PhD, MPH
Memorial Sloan Kettering’s Bob Li served as principal investigator of the CodeBreaK 100 trial, the largest clinical trial conducted to date exclusively for patients with the KRAS G12C mutation.
Dr. Alicia Latham, Dr. Michael Walsh, Dr. Zsofia Stadler, and Megha Ranganathan
Feature
MSK investigators are leading research focused on understanding how hereditary DNA mutations affect cancer development and therapy, and how to best treat people who carry these inherited risks in their genes.
Tumor mutation model
Finding
Investigators confirmed that people whose tumors have a high tumor mutational burden and were treated with immunotherapy lived longer.
MSK scientist Britta Weigelt and MSK physician-scientist Sarah Kim
Learn how MSK’s liquid biopsy test, MSK-ACCESS, could improve the lives of patients with gynecologic cancers.
Illustration of cells with blue nuclei that have green DNA bits floating in the cytoplasm
In the Lab
Researchers have discovered that cancer cells may hijack an immune response to spread from a primary tumor to distant organs.
electron micrograph of a natural killer cell
In the Lab
A drug combination that halts tumor cell division can stir the immune system into taking action.
Dr. Prasad Adusumilli sits at a computer. A patient’s face and a chest image are on the screen.
Feature
Whether you’ve been diagnosed with a rare cancer or one that’s more common, MSK doctors can provide a second opinion.